Eye involvement in cerebral malaria.

A. Mahdi,M. Hasan,H. Khan,R. Khanna,S. Ahmad

DOI: https://doi.org/10.1093/INFDIS/160.6.1092

1989-12-01

Abstract:

What problem does this paper attempt to address?

IgA Vasculitis:A Review on Diagnosis and Management

ZHONG Xinyue,SONG Yan,QIAO Jianjun

2022-01-01

Abstract:IgA vasculitis, also known as Henoch-Sch9nlein purpura, is a small blood vessel vasculitis with a high incidence in children. Its main manifestation is symmetrically distributed palpable purpura. It can involve joints, gastrointestinal tract, kidney and other systems. The diagnosis of IgA vasculitis is based on the comprehensive consideration of typical skin lesions and other symptoms of systemic involvement. The evaluation and classification of IgA vasculitis nephritis are closely related to treatment and prognosis. The treatment of IgA vasculitis is mainly supportive therapy based on symptoms. Glucocorticoids is the first-line choice of drugs. Strong evidence is needed to confirm the efficacy of second-line treatments such as mycophenol mofetil and cyclophosphamide.
Pathogenesis of IgA Vasculitis: An Up-To-Date Review

Yan Song,Xiaohan Huang,Guizhen Yu,Jianjun Qiao,Jun Cheng,Jianyong Wu,Jianghua Chen

DOI: https://doi.org/10.3389/fimmu.2021.771619

IF: 7.3

2021-01-01

Frontiers in Immunology

Abstract:Immunoglobin A (IgA) vasculitis (IgAV), formerly called the Henoch-Schonlein purpura (HSP), is a small vessel vasculitis, characterized by IgA1-dominant immune deposition at diseased vessel walls. IgAV is the most common form of vasculitis in children; typical symptoms include palpable purpura, arthritis or arthralgia, abdominal pain, and hematuria or proteinuria. Galactose-deficient IgA1 is detected in the tissues of the kidney and skin in patients with IgAV; it forms immune complexes leading to subsequent immune reactions and injuries. This report provides the recent advances in the understanding of environmental factors, genetics, abnormal innate and acquired immunity, and the role of galactose-deficient IgA1 immunocomplexes in the pathogenesis of IgAV.
Progress in Pathogenesis of Immunoglobin A Nephropathy

Jemima C Stanley,Hong Deng

DOI: https://doi.org/10.7759/cureus.8789

2020-01-01

Abstract:The understanding of the pathogenesis of any disease is the key to effective and specific treatment of the disease.immunoglobulin A (IgA) nephropathy is an autoimmune disease of the kidney.Oxford MEST classification is commonly used to stratify patients according to the severity of the disease.Patients with IgA nephropathy seem to produce anti-GalNAc antibodies against a particularly defective IgA1.This immune complex deposits in the kidneys, leading to a type 3 hypersensitivity reaction which ultimately damages the kidneys.People of a certain genetic background and who experience upregulation of certain defective receptors seem to develop primary IgA nephropathy.Secondary IgA nephropathy could be due to dysbiosis of the microbiota in the gut, compromised gut immunity or other gut pathologies, pulmonary function abnormalities, or amyloidosis.Overproduction of IgA due to plasma cell dyscrasia or reduced clearance of IgA due to liver abnormalities could also be potential causes.Genes that predispose individuals to IgA nephropathy and intestinal abnormalities, such as Celiac disease, seem to overlap and these people tend to have a poorer prognosis and need to be placed on more intensive treatment regimens.IgA Vasculitis seems to be a systemic form of IgA nephropathy, whereby IgA deposits systemically and leads to multiple disease manifestations.Patients in high-risk groups could also be prophylactically screened for the disease and closely monitored by immunohistochemical methods such as an enzyme-linked immunosorbent assay (ELISA) or identified by genetic testing.Currently, the major treatment regimens involve supportive therapy or immunosuppressive therapy which has major side effects.More specific treatment methods such as monoclonal antibodies, immunoglobulin replacement therapy, or low-antigencontent diet could also be looked into as potential treatment options.Stem cell replacement, by way of bone marrow transplant and tonsillectomy, has been suggested as a treatment option in patients with indications.
Venous Sinus Thrombosis in a Case of Immunoglobulin A Vasculitis and a Systemic Review of Literature

Qi Zheng,Qian He,Hongxia Huang,Meiping Lu

DOI: https://doi.org/10.1111/1756-185x.14529

2023-01-01

International Journal of Rheumatic Diseases

Abstract:ObjectivesTo describe venous sinus thrombosis involved in immunoglobulin A (IgA) vasculitis and identify the clinical features and imaging findings of this rare disease. MethodsWe describe a case with venous sinus thrombosis related to IgA vasculitis, and a systematic review of previously reported cases in the literature. ResultsA 10-year-old boy presented with recurrent petechiae of the lower extremities with abdominal pain, and was diagnosed as having IgA vasculitis. He had a sudden headache during the treatment of steroids, and venous sinus thrombosis was diagnosed according to magnetic resonance imaging. Venous sinus thrombosis is a rare complication of IgA vasculitis. Based on the systematic review, most of these reported cases who developed venous sinus thrombosis had multi-system involvement, which included skin, joints, gastrointestinal tract or kidneys. Sudden headache was the most common symptom of central venous sinus thrombosis. Some cases may also manifest as seizures and blindness. The sagittal sinus was the most common site of thrombosis. Magnetic resonance image, magnetic resonance venography, or computed tomography angiography were helpful for early diagnosis of this disease. Combination therapy of steroids and anticoagulation medication was effective in rapidly reliving clinical symptoms. ConclusionsSudden headache in patients with IgA vasculitis requires vigilance for the possibility of central venous sinus thrombosis. Anti-inflammatories combined with anticoagulant therapy were needed for these patients.
Galactose-deficient IgA1 in skin and serum from patients with skin-limited and systemic IgA vasculitis

Matthias Neufeld,Karen Molyneux,Karin I Pappelbaum,Sarah Mayer-Hain,Christina von Hodenberg,Jan Ehrchen,Jonathan Barratt,Yusuke Suzuki,Cord Sunderkötter

DOI: https://doi.org/10.1016/j.jaad.2019.03.029

Abstract:Background: IgA vasculitis (IgAV) encompasses a systemic form involving kidneys, gut, skin, or joints, and a skin-limited form. One characteristic feature of systemic IgAV is deposition of galactose-deficient IgA1 (GD-IgA1) in kidneys (as in IgA nephropathy). The relevance of GD-IgA1 for cutaneous vasculitis is unknown. Objective: We investigated whether GD-IgA1 is deposited perivascularly in systemic and also skin-limited IgAV and whether its serum levels differ between both forms. Methods: In a case-control study, deposition of GD-IgA1 was analyzed immunohistochemically by KM55 antibody in skin biopsy specimens from 12 patients with skin-limited IgAV and 4 with systemic IgAV. GD-IgA1 levels were compared by enzyme-linked immunosorbent assay in sera from 15 patients each with skin-limited and systemic IgAV and from 11 healthy individuals. Results: All biopsy samples from systemic IgAV, and also from skin-limited IgAV, revealed perivascular GD-IgA1 deposition. The average GD-IgA1 concentration in serum was significantly higher in systemic IgAV than in skin-limited IgAV, despite overlap between the groups. Limitations: Although high GD-IgA1 levels may be predictive of systemic IgAV, patient numbers were too low to determine cutoff values for systemic versus skin-limited IgAV. Conclusion: Perivascular GD-IgA1 deposition is a prerequisite for systemic and skin-limited IgAV; however, high GD-IgA1 levels in some patients with systemic IgAV suggest a dose-dependent effect of GD-IgA1 in IgAV.
[Isolation of a virus closely related to the Japanese encephalitis virus from a lot of mosquitoes in Saigon].

Nguyen Thi Kim Thoa,D. Beytout,Do Van Quy

Abstract:
Pathophysiology and clinical manifestations of immune complex vasculitides

Cord Sunderkötter,Linda Golle,Evangéline Pillebout,Christiane Michl

DOI: https://doi.org/10.3389/fmed.2023.1103065

2023-03-03

Abstract:Immune complex (IC) vasculitides present inflammations of vessel walls associated with perivascular deposition of immunoglobulins (Igs), mostly ICs. They encompass systemic and skin-limited variants of IgA vasculitis (IgAV), cryoglobulinemic vasculitis (CV), rheumatoid, lupus, and hypocomplementemic vasculitides, serum sickness cutaneous IgM/IgG (non-IgA) vasculitis, and recurrent macular (hypergammaglobulinemic or exertion-induced) vasculitis. Serum sickness and CV fulfill the criteria of a type III hypersensitivity immune reaction as large lattices of the IC precipitate at vessel walls and activate polymorphonuclear neutrophils (PMNs). Immunoglobulin-A vasculitis differs with regard to the causes of perivascular deposition of ICs since here many IgA1 molecules are hypoglycosylated (Gd-IgA1), which appears to facilitate their perivascular deposition in skin and mesangium (via e.g. CD71). The reasons for increased generation of immunoglobulins or formation of IC and their perivascular deposition in either skin or systemic organs are different and not fully explored. A common denominator of OC vasculitides is the activation of PMNs near the vessel wall via Fcy or Fcα receptors. Acute episodes of IgAV additionally require PMNs to become preactivated by IgA1 or by IC already in circulation. This intravascular priming results in increased adherence and subsequently vessel-destructive NETosis when they encounter IgA deposited at the vessel walls. Binding of IgA1 to PMNs in blood stream is associated with increased serum levels of hypogalactosidated IgA1. The characteristic clinical picture of IgAV (and also of so-called IgG/IgM vasculitis) comprises palpable or retiform purpura with a clear predilection for lower legs, probably due to stasis-related reduction in blood velocity, while in other IC vasculitides, additional factors influence the sites of vasculitides. Our knowledge of distinct forms and different pathophysiological pathways of IC vasculitides may lead to in efficacious or targeted therapies. Antibodies to complement components or intestinal budesonide for IgAV are promising agents (the latter suppresses the pathophysiologically related IgA nephropathy by reducing the generation of mucosal IgA.
Clinicopathological Features of Antineutrophil Cytoplasmic Antibodies Associated Vasculitis with Glomerular IgA Deposits

Hua Zhou,Ma Yanhong,Chen Liangliang,Yu Binfeng,Xu Ying,Wang Huiping,Chen Jianghua,Han Fei

DOI: https://doi.org/10.3760/cma.j.issn.1001-7097.2018.03.003

2018-01-01

Abstract:Objective To investigate the clinical manifestations,renal pathology and prognosis of antineutrophil cytoplasmic antibody-associated small-vessel vasculitis (AAV) accompanied with renal glomerular IgA deposition.Methods A retrospective analysis was performed at the First Affiliated Hospital of Zhejiang University College of Medicine.Patients diagnosed with AAV associated renal injury by renal biopsy from February 2004 to February 2017 were enrolled.Patients with antiglomerular basement membrane antibody-mediated nephritis,systemic lupus erythematosus nephritis,Henoch Schonlein purpura nephritis,hepatitis B virus associated nephritis and other known etiology were excluded.According to immunofluorescence examination,the patients were divided into IgA deposition group and pauci-immune complex deposition group.The differences in clinical manifestation,pathological features and prognosis were compared between groups.Results A total of 150 AAV cases were included,among which 25 cases were with IgA deposition and 125 cases with pauci-immune complex deposition.The level of serum albumin in IgA deposition group was higher than that in pauci-immune complex deposition group [(35.0±6.2) g/L vs (32.6±5.3) g/L,P=0.049],but the titer of MPO-ANCA was lower [24.8(10.4,71.8) U/ml vs 63.0(21.9,100.0) U/ml,P=0.044] in IgA deposition group.There was no significant difference between two groups in other laboratory indexes and renal pathological findings.The median follow-up time was 15.2 months in IgA deposition group and 8.9 months in pauci immune complex deposition group.During the follow-up there were 8 patients (32.0％) in IgA deposition group and 29 patients (23.2％) in pauci immune complex deposition group on maintaining dialysis;2 patients (8.0％) in IgA deposition group and 7 patients (5.6％) in pauci immune complex deposition group died.There was no significant difference between two groups in patients' outcomes.Conclusions AAV patients with glomerular IgA deposition and AAV patients with typical glomerular immunoglobulin complex deposition are similar as regards clinical appearance and prognosis.
The Clinicopathologic Characteristics and Complement Activation of Antineutrophil Cytoplasmic Antibody-associated Vasculitides with Glomerular IgA Deposition

Yanhong Ma,Liangliang Chen,Ying Xu,Quan Han,Binfeng Yu,Jie Zhao,Zhou Hua,Yi Yang,Jianghua Chen,Fei Han

DOI: https://doi.org/10.1097/pai.0000000000000819

IF: 1.992

2019-01-01

Applied Immunohistochemistry & Molecular Morphology

Abstract:The renal injury caused by antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are characterized by few or no immune deposits in glomerulus. A growing number of AAV patients with glomerular immunoglobulin (Ig)A deposits have been reported. We retrospectively investigated all AAV patients with glomerular IgA deposits diagnosed in our center. Serum galactose-deficient IgA1 (Gd-IgA1) level and glomerular Gd-IgA1 and IgA staining were measured. Moreover, we detected complement pathway components in their sera. A total of 168 AAV patients were enrolled, including 26 patients with glomerular IgA deposition and 142 patients with pauci-immune-complex deposition. The AAV patients with IgA deposition had a tendency of lower systemic disease activity, presenting with lower erythrocyte sedimentation rate, lower myeloperoxidase-ANCA, and tendency of lower C reactive protein and Birmingham Vasculitis Activity Score. For renal injury, there were no significant differences in clinical data, pathologic parameters, or renal outcome between groups. The serum level of Gd-IgA1 and intensity of glomerular Gd-IgA1 staining in IgA deposition AAV patients were similar to IgA nephropathy patients. All patients in the IgA nephropathy group and AAV groups with or without IgA deposition had the activation of the alternative complement pathway, whereas AAV patients with IgA deposition also had the activation of the classic complement pathway. Correlation analysis showed serum C1q level correlated directly with serum globulin and IgA levels. In conclusion, AAV patients with IgA deposition had the basis of IgA nephropathy and may present lower systemic disease activity. But it differs from pauci-immune AAV or IgA nephropathy by the possible activation of the classic complement pathway.
Serum Syndecan-1 Levels in Patients with Immunoglobulin A Vasculitis in Children

Xinyi Jia,Zhenya Zhu,Jing Miao,Linqian Zhang,Xiaobing Li,Yunguang Bao,Mizu Jiang

DOI: https://doi.org/10.1016/j.jped.2022.01.004

IF: 2.99

2022-01-01

Jornal de Pediatria

Abstract:Objective: The aim of this study was to evaluate the serum Syndecan-1 (SDC-1) levels in patients with immunoglobulin-A vasculitis (IgAV) in children and its relation with gastrointestinal involvements. Methods: Sixty-eight children with IgAV and 48 healthy children were enrolled in this cross-sectional study. Clinical and related laboratory data were collected from a computerized hospital database. Serum SDC-1 was collected on admission prior to treatment. Results: Forty-eight patients fully met the IgAV diagnostic criteria at admission (IgAV group), 20 patients with rash only and diagnosed IgAV during hospitalization (Purpura group). In IgAV group, 30 patients with gastrointestinal involvements (IgAV-GI group) and 18 patients without gastrointestinal involvements (IgAV-NGI group). SDC-1 serum levels were significantly higher in the IgAV group (86.37 ng/mL (IQR 59.16-117.14 ng/mL)) than in the controls (20.37 ng/mL (IQR 15.52-26.45 ng/mL)) and the Purpura group (32.66 ng/mL (IQR 14.87-49.89 ng/mL)). Additionally, SDC-1 (OR = 1.08) was independently associated with IgAV with a cut-off value (sensitivity and specificity) of 66.55 ng/mL (68.8%, 95.0%), and the area under the curve was 0.908. The serum SDC-1 levels of the IgAV-GI group (106.92 +/- 50.12 ng/mL) were significantly higher than those in the IgAV-NGI group (67.52 +/- 17.59 ng/mL). Logistic regression analysis showed that SDC1 (OR = 1.03) was independently associated with IgAV-GI with a cut-off value of 89.39 ng/mL. Conclusions: SDC-1 serum levels may mirror vascular endothelium injury and mucosal damage in IgAV. Its applicability as a surrogate biomarker in IgAV remains to be determined. (c) 2022 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ 4.0/).
Exploring the Diagnostic Odyssey of IgA Vasculitis

Irene Rosmaninho,Beatriz Simão-Parreira,Carolina Leal,Leila Cardoso,Jorge Almeida

DOI: https://doi.org/10.7759/cureus.68170

2024-08-30

Cureus

Abstract:IgA vasculitis is a form of small vessel vasculitis characterized by IgA immune complex deposition. Although primarily affecting children, it can also occur in adults, often with more severe manifestations and a higher risk of chronic kidney disease (CKD). The authors present the case of a 77-year-old man with significant cardiovascular risk and atrial fibrillation who was admitted to the emergency department (ED) with pruritic and painful palpable purpuric rash, weight loss, and asthenia persisting for approximately one month prior to presentation. Laboratory findings revealed normocytic normochromic anemia, worsening renal function, elevated inflammatory markers, and leukoerythrocyturia. Initially diagnosed as infectious purpura associated with urinary tract infection, the patient was discharged with a prescription for antibiotics (cefixime). Subsequent worsening of the skin lesions, constitutional symptoms, and gross hematuria prompted a second visit to the ED, and the persistent deterioration of kidney function and inflammatory parameters led to admission for further investigation and consideration of a kidney biopsy. This case report describes the etiological investigation, providing a brief review of the typical characteristics of this disease and highlighting the importance of certain factors in establishing the diagnosis, notably the need and timing of a biopsy of the affected organ for a definitive diagnosis. Additionally, the clinical case underscores the diagnostic challenge, particularly when histological confirmation is elusive.
Childhood IgA Vasculitis (Henoch Schonlein Purpura)—Advances and Knowledge Gaps

Louise Oni,Sunil Sampath

DOI: https://doi.org/10.3389/fped.2019.00257

IF: 3.569

2019-06-27

Frontiers in Pediatrics

Abstract:Immunoglobulin A vasculitis (IgAV; formerly Henoch Schonlein Purpura) is the most common form of childhood vasculitis. It can occur in any age and peaks around 4–6 years old. It demonstrates seasonal variation implicating a role for environmental triggers and geographical variation. The diagnosis is made clinically and 95% of patients will present with a rash, together with any from a triad of other systems—gastrointestinal, musculoskeletal, and renal. Most cases of IgAV in children have an excellent outcome. Treatment may be required during the acute phase for gastrointestinal involvement and renal involvement, termed IgAV nephritis (previously HSP nephritis), is the most serious long-term manifestation accounting for ~1–2% of all childhood end stage kidney disease (ESKD). It therefore requires a period of renal monitoring conducted for 6–12 months. Patients presenting with nephrotic and/or nephritic syndrome or whom develop significant persistent proteinuria should undergo a renal biopsy to evaluate the extent of renal inflammation and there are now international consensus guidelines that outline the indications for when to do this. At present there is no evidence to support the use of medications at the outset in all patients to prevent subsequent renal inflammation. Consensus management guidelines suggest using oral corticosteroids for milder disease, oral, or intravenous corticosteroids plus azathioprine or mycophenolate mofetil or intravenous cyclophosphamide for moderate disease and intravenous corticosteroids with cyclophosphamide for severe disease. Angiotensin system inhibitors act as adjunctive treatment for persisting proteinuria and frequently relapsing disease may necessitate the use of immunosuppressant agents. Renal outcomes in this disease have remained static over time and progress may be hindered due to many reasons, including the lack of reliable disease biomarkers and an absence of core outcome measures allowing for accurate comparison between studies. This review article summarizes the current evidence supporting the management of this condition highlighting recent findings and areas of unmet need. In order to improve the long term outcomes in this condition international research collaboration is urgently required.

pediatrics
Pathogenesis and treatment progress of antineutrophil cytoplasmic antibody-associated vasculitis

Shuyuan YU,Lin ZHENG,Fei HAN

DOI: https://doi.org/10.12092/j.issn.1009-2501.2018.02.022

2018-01-01

Abstract:Vasculitis is an autoimmune disease which may cause nonspecific inflammation and necrosis of the blood vessels.According to degree of the vascular involvement,vasculitis divides into small vasculitis,moderate vasculitis and large vasculitis.Antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) which belongs to the small vasculitis includes granulomatous polyangiitis (GPA) microscopic polyangiitis (MPA) and eosinophilic granulomatous polyangiitis (EGPA).Different organs of the whole body could be involved and the active period is extremely dangerous.Untimely treatment can result in high mortality.This paper briefly reviews the pathogenesis and treatment progress of AAV.
Insight into the Interplay of Gd-IgA1, HMGB1, RAGE and PCDH1 in IgA Vasculitis (IgAV)

Martina Held,Ana Kozmar,Mario Sestan,Daniel Turudic,Nastasia Kifer,Sasa Srsen,Alenka Gagro,Marijan Frkovic,Marija Jelusic

DOI: https://doi.org/10.3390/ijms25084383

2024-04-16

Abstract:The pathogenesis of IgAV, the most common systemic vasculitis in childhood, appears to be complex and requires further elucidation. We aimed to investigate the potential role of galactose-deficient immunoglobulin A1 (Gd-IgA1), high-mobility group box 1 (HMGB1), receptor for advanced glycation end products (RAGE) and protocadherin 1 (PCDH1) in the pathogenesis of IgAV. Our prospective study enrolled 86 patients with IgAV and 70 controls. HMGB1, RAGE, Gd-IgA1 and PCDH1 in serum and urine were determined by the enzyme-linked immunosorbent assay (ELISA) method at the onset of the disease and after a six-month interval in patients and once in the control group. Serum concentrations of HMGB1, RAGE and PCDH1 and urinary concentrations of HMGB1, RAGE, Gd-IgA1 and PCDH1 were significantly higher in patients with IgAV than in the control group (p < 0.001). Concentrations of HMGB1 (5573 pg/mL vs. 3477 pg/mL vs. 1088 pg/mL, p < 0.001) and RAGE (309 pg/mL vs. 302.4 pg/mL vs. 201.3 pg/mL, p = 0.012) in the serum of patients remained significantly elevated when the disease onset was compared with the six-month follow-up interval, and thus could be a potential marker of disease activity. Urinary concentration of HMGB1 measured in the follow-up period was higher in patients with nephritis compared to IgAV without nephritis (270.9 (146.7-542.7) ng/mmol vs. 133.2 (85.9-318.6) ng/mmol, p = 0.049) and significantly positively correlated with the urine albumine to creatinine ratio (τ = 0.184, p < 0.05), the number of erythrocytes in urine samples (τ = 0.193, p < 0.05) and with the outcome of nephritis (τ = 0.287, p < 0.05); therefore, HMGB1 could be a potential tool for monitoring patients with IgAV who develop nephritis. Taken together, our results imply a possible interplay of Gd-IgA1, HMGB1, RAGE and PCDH1 in the development of IgAV. The identification of sensitive biomarkers in IgAV may provide disease prevention and future therapeutics.
Henoch-Schönlein Purpura (IgA Vasculitis): Rapid Evidence Review

Brian V Reamy,Jessica T Servey,Pamela M Williams

2020-08-15

Abstract:Henoch-Schönlein purpura, now called immunoglobulin A (IgA) vasculitis, is a systemic, immune complex-mediated, small-vessel leukocytoclastic vasculitis characterized by nonthrombocytopenic palpable purpura, arthritis, and abdominal pain. It is the most common vasculitis in children but can also occur in adults. Diagnostic testing is required only to exclude other etiologies of purpura, to identify renal involvement, and, if indicated, to determine its extent with biopsy. Imaging or endoscopy may be needed to assess organ complications. IgA vasculitis spontaneously resolves in 94% of children and 89% of adults, making supportive treatment the primary management strategy. However, a subset of patients experience renal involvement that can persist and relapse years later. Additional complications can include gastrointestinal bleeding, orchitis, and central nervous system involvement. Systematic reviews have shown that steroids do not prevent complications and should not be used prophylactically. However, randomized trials have demonstrated success with high-dose steroids, cyclosporine, and mycophenolate in treating glomerulonephritis and other complications. Long-term prognosis depends on the extent of renal involvement. Six months of follow-up is prudent to assess for disease relapse or remission.
A Review of the Pathogenesis of IgA Vasculitis Nephritis in Children

Qianqian Li,Rong Chen,Hongjin An,Yuying Tang,Baowang Yang

DOI: https://doi.org/10.5812/ijp-150310

2024-11-11

Iranian Journal of Pediatrics

Abstract:: In children, IgA Vasculitis (IgAV), formerly known as Henoch-Schönlein purpura, is a common kidney illness primarily caused by anaphylactoid purpura. It is highly prevalent among youngsters, often presenting with symptoms such as skin purpura, abdominal pain, and hematuria. In some cases, IgA vasculitis nephritis (IgAVN) may progress to chronic kidney disease (CKD), exacerbating renal function impairment and negatively impacting patient prognosis. To effectively develop preventive and therapeutic strategies for pediatric IgAVN, a comprehensive understanding of its pathogenesis is crucial. This review discusses the involvement of key biological markers, including galactose-deficient IgA1, C-reactive protein, and inflammatory cytokines, in the disease's pathophysiology. Additionally, it provides an overview of the specific diagnostic markers and clinical management strategies pertinent to this condition.

pediatrics
Mutant gene--teratogen interaction studied on different genetic backgrounds.

V. Bílá,V. Křen

Folia biologica

Abstract:
Severe Gastrointestinal Involvement in Pediatric IgA Vasculitis: a Retrospective Single-Center Cohort Study in China.

Yifan Li,Xiaomei Zhang,Haimei Liu,Guomin Li,Wanzhen Guan,Tao Zhang,Qiaoqian Zeng,Yinv Gong,Hong Xu,Li Sun

DOI: https://doi.org/10.3389/fped.2023.1194214

IF: 3.569

2023-01-01

Frontiers in Pediatrics

Abstract:ObjectivesThe study aimed to describe the characteristics of gastrointestinal (GI) involvement in a cohort of hospitalized children with IgA vasculitis (IgAV) in China.MethodWe reviewed the records of hospitalized IgAV patients from January 2014 to December 2020 at one tertiary medical center. The patients were divided into the severe GI group and the non-severe GI group according to the presence of massive GI bleeding and complications. The clinical manifestations, laboratory factors, and treatment were analyzed between the two groups.ResultsA total of 1,179 patients were hospitalized due to IgAV. GI involvement was noted in 50% (589) of the patients, of whom 288 (48.9%) had severe GI involvement. GI complications were observed in 34 patients with IgAV with GI involvement. Rare onset age (<3 years or within 13-17 years), purpura above the waist, vomiting, high neutrophil-to-lymphocyte ratio, and decreased serum albumin were factors associated with severe GI involvement. Frequencies of renal involvement and biopsy-proven nephritis were higher in the severe GI group. The most commonly used medications were corticosteroids (100.0%) in the severe GI group. The maximum corticosteroid dose was higher (2.9 vs. 2.0 mg/kg), and more second-line therapies were needed (30.9% vs. 16.94%) in the severe GI group.ConclusionsSevere GI involvement in children is common in our center. Rare onset age, purpura above the waist, vomiting, high neutrophil-to-lymphocyte ratio, and decreased serum albumin are associated with severe GI involvement. Patients with severe GI involvement need higher doses of corticosteroids and second-line therapy.
IgA Vasculitis and IgA Nephropathy: Same Disease?

Evangeline Pillebout

DOI: https://doi.org/10.3390/jcm10112310

IF: 3.9

2021-05-25

Journal of Clinical Medicine

Abstract:Many authors suggested that IgA Vasculitis (IgAV) and IgA Nephropathy (IgAN) would be two clinical manifestations of the same disease; in particular, that IgAV would be the systemic form of the IgAN. A limited number of studies have included sufficient children or adults with IgAN or IgAV (with or without nephropathy) and followed long enough to conclude on differences or similarities in terms of clinical, biological or histological presentation, physiopathology, genetics or prognosis. All therapeutic trials available on IgAN excluded patients with vasculitis. IgAV and IgAN could represent different extremities of a continuous spectrum of the same disease. Due to skin rash, patients with IgAV are diagnosed precociously. Conversely, because of the absence of any clinical signs, a renal biopsy is practiced for patients with an IgAN to confirm nephropathy at any time of the evolution of the disease, which could explain the frequent chronic lesions at diagnosis. Nevertheless, the question that remains unsolved is why do patients with IgAN not have skin lesions and some patients with IgAV not have nephropathy? Larger clinical studies are needed, including both diseases, with a common histological classification, and stratified on age and genetic background to assess renal prognosis and therapeutic strategies.

medicine, general & internal
A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and Future

Dinah V Parums,Dinah V. Parums

DOI: https://doi.org/10.12659/msm.943912

2024-01-25

Medical Science Monitor

Abstract:The clinical association of purpura, arthralgia, and arthritis was first described in 1837 in a publication by Johann Lukas Schönlein, a German physician. In 1874, Eduard Henoch, a student of Schönlein, reported cases of children with purpura, abdominal pain, bloody diarrhea, and joint pain. IgA vasculitis, or Henoch-Schönlein purpura, is a systemic hypersensitivity vasculitis caused by the deposition of immune complexes in small blood vessels, including the renal glomeruli and mesangium. In the skin, the presentation is with non-thrombocytopenic purpura or urticaria. Worldwide, IgA nephropathy is the most common cause of primary glomerulonephritis. Detection of IgA deposition in small blood vessels and the renal glomeruli is diagnostic in most cases. This article aims to review the history, current classification, epidemiology, presentation, and diagnosis of IgA vasculitis and nephropathy, disease associations or trigger factors, including infections, vaccines, and therapeutic agents, and highlights some future approaches to improve diagnosis and clinical management.

medicine, research & experimental

Eye involvement in cerebral malaria.

IgA Vasculitis:A Review on Diagnosis and Management

Pathogenesis of IgA Vasculitis: An Up-To-Date Review

Progress in Pathogenesis of Immunoglobin A Nephropathy

Venous Sinus Thrombosis in a Case of Immunoglobulin A Vasculitis and a Systemic Review of Literature

Galactose-deficient IgA1 in skin and serum from patients with skin-limited and systemic IgA vasculitis

[Isolation of a virus closely related to the Japanese encephalitis virus from a lot of mosquitoes in Saigon].

Pathophysiology and clinical manifestations of immune complex vasculitides

Clinicopathological Features of Antineutrophil Cytoplasmic Antibodies Associated Vasculitis with Glomerular IgA Deposits

The Clinicopathologic Characteristics and Complement Activation of Antineutrophil Cytoplasmic Antibody-associated Vasculitides with Glomerular IgA Deposition

Serum Syndecan-1 Levels in Patients with Immunoglobulin A Vasculitis in Children

Exploring the Diagnostic Odyssey of IgA Vasculitis

Childhood IgA Vasculitis (Henoch Schonlein Purpura)—Advances and Knowledge Gaps

Pathogenesis and treatment progress of antineutrophil cytoplasmic antibody-associated vasculitis

Insight into the Interplay of Gd-IgA1, HMGB1, RAGE and PCDH1 in IgA Vasculitis (IgAV)

Henoch-Schönlein Purpura (IgA Vasculitis): Rapid Evidence Review

A Review of the Pathogenesis of IgA Vasculitis Nephritis in Children

Mutant gene--teratogen interaction studied on different genetic backgrounds.

Severe Gastrointestinal Involvement in Pediatric IgA Vasculitis: a Retrospective Single-Center Cohort Study in China.

IgA Vasculitis and IgA Nephropathy: Same Disease?

A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and Future